- Does your jurisdiction advise administering RSV preventive antibody products to infants beyond March this year? See available information.
- Federal court issues stay of recent changes to federal vaccine policy; “ACIP as currently constituted cannot meet”
- “How Are mRNA and Protein-Based COVID-19 Vaccines Different?” See this 3-minute video, part of the Ask the Experts Video Series on YouTube.
- Immunize.org updates "Strategies to Improve Adult Vaccination Coverage"
- Immunize.org updates “Skills Checklist for Vaccine Administration”
- Influenza activity declining, RSV persists in the North, and COVID-19 declining nationally; vaccination still offers protection
- FDA expands license for GSK’s RSV vaccine (Arexvy) to include high-risk adults age 18 to 49 years
- Vaccines in the news
- Child Neurology Society offers video discussing neurologic complications of measles infection
- Adolescent Immunization Action Week is April 6–10; Unity Consortium posts toolkit to help you prepare
- Laminated VIS QR code tables deliver CDC VISs directly to your patients’ smartphone (Spanish translation version also available). Now shipping!
- Immunize.org's elegant "Vaccination Saves Lives" blue enamel pins make wonderful graduation gifts or workplace recognitions
- Updated 65+ Flu Defense website offers resources for healthcare professionals serving older adults
- Virtual: Unity Consortium hosts webinar moderated by Chelsea Clinton, “Who Influences Young People’s Health Choices? The New Conversation About Vaccines” on April 8 at 12:00 p.m. (ET)
- Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about our About Us, Publication Archives, and Vaccine Timeline web content on April 8 at 4:00 p.m. (ET) or April 9 at 12:00 p.m. (ET). Recorded sessions archived.
For the 2025–26 RSV season, two preventive antibody product options are available for infants: nirsevimab (Beyfortus, Sanofi) and clesrovimab (Enflonsia, Merck). Typically, RSV preventive antibody products are recommended to be administered from October 1 through March 31 in most of the continental United States, to correspond with the typical seasonality of RSV.
This season, significant RSV activity is continuing later than normal in some parts of the continental United States. Data from the National Respiratory and Enteric Viruses Surveillance System indicates that elevated RSV activity may continue into April in several regions. As a result, CDC has encouraged state, local, and territorial public health officials to review available RSV data in their jurisdiction and consider whether to extend RSV preventive antibody administration beyond March, particularly for newborns. Insurance coverage is expected to continue for use of RSV antibodies beyond March.
The Association of Immunization Managers (AIM), which represents the 66 jurisdictions (states, cities, and U.S. territories) directly funded by CDC for immunization activities, has collected information from some jurisdictions about their RSV preventive antibody product recommendations at this point. Jurisdictions that already recommend year-round use of RSV preventive antibody products in babies (e.g., Hawaii) are not included. If you do not see your jurisdiction, or have questions, contact your jurisdiction’s immunization program.

IZ Express will provide updates to information as it is provided to us. If you do not see your jurisdiction, contact them directly for information.
Related Links
- AAP: RSV Immunization Administration Frequently Asked Questions web page
- Immunize.org: Standing Orders for Administering Nirsevimab RSV Preventive Antibody (Beyfortus, by Sanofi) to Infants and High-Risk Young Children (PDF)
- Immunize.org: Standing Orders for Administering Clesrovimab RSV Preventive Antibody (Enflonsia, by Merck) to Infants (PDF)
- Immunize.org: Vaccines A–Z: RSV (Respiratory Syncytial Virus) main page
- Association of Immunization Managers: Immunization Program Directory web page
Federal court issues stay of recent changes to federal vaccine policy; “ACIP as currently constituted cannot meet”
On March 16, U.S. District Judge Brian Murphy of the District of Massachusetts blocked CDC immunization schedule changes made since June 2025 and stayed ACIP member appointments. The major consequences of this decision are:
- Order stays the pediatric vaccine schedule published on January 5, 2026
- The Secretary’s 13 appointments to the ACIP are stayed for likely having violated the Federal Advisory Committee Act
- All votes taken by the now-stayed ACIP are stayed
- "ACIP as currently constituted cannot meet"
The stay was issued as part of a lawsuit filed by these plaintiffs: the American Academy of Pediatrics, American Public Health Association, American College of Physicians, Infectious Diseases Society of America, Society for Maternal-Fetal Medicine, Massachusetts Chapter of the American Academy of Pediatrics, Massachusetts Public Health Alliance, and Jane Does 1, 2, and 3.
The plaintiffs in the lawsuit, AAP et. al. v Kennedy et. al., challenges recent HHS actions that they assert did not follow longstanding, evidence-based procedures traditionally used to develop national vaccine guidance. The plaintiffs’ position is that these actions undermine public health, disrupt clinical practice, and erode confidence in immunization policy.
The Court earlier ruled that the lawsuit may proceed and denied the government's motion to dismiss. HHS may choose to appeal this decision to stay HHS actions while the lawsuit proceeds. IZ Express will keep readers informed of further developments and their impact on clinical immunization practice.
For more information, see the Common Health Coalition’s 2-page summary of the AAP v. Kennedy Ruling and what it means for clinicians and families.
Related Links
- U.S. District Court: Memorandum and Order on Plaintiffs' Motion for Preliminary Injunction (3/16/26)
- AAP news release: AAP Statement on Historic Ruling in Vaccine Lawsuit (3/16/26)
- PR Newswire: CORRECTION—Federal Judge Blocks Immunization Schedule Changes, Stays ACIP Member Appointments (3/16/26)
- Common Health Coalition: Summary of the AAP v. Kennedy Ruling (3/16/26)
“How Are mRNA and Protein-Based COVID-19 Vaccines Different?” See this 3-minute video, part of the Ask the Experts Video Series on YouTube.
This week, our featured episode from the Ask the Experts Video Series is titled How Are mRNA and Protein-Based COVID-19 Vaccines Different? The video describes how the mRNA vaccines deliver a piece of mRNA that tells the body's cells to make a version of the COVID-19 spike protein. Protein-based vaccine delivers the premade spike protein directly. Both vaccines achieve the same end result by training the immune system to recognize and fight the virus, reducing the risk of serious disease.
The 3-minute video is available on our YouTube channel, along with our full collection of quick video answers to popular Ask the Experts questions.

Like, follow, and share Immunize.org’s social media accounts and encourage colleagues and others interested in vaccination to do likewise.
- Facebook at ImmunizeOrg
- Instagram at ImmunizeOrg
- LinkedIn at ImmunizeOrg
- YouTube at ImmunizeOrg
Immunize.org updated its Strategies to Improve Adult Vaccination Coverage document for healthcare providers. Edits were primarily made to update references and links to external resources.

Related Links
- Immunize.org: Clinical Resources: Adult Vaccination main page
- Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria
Immunize.org updated its Skills Checklist for Vaccine Administration document for healthcare staff who administer immunizations. Edits were made to update the links to external resources.

Related Links
- Immunize.org: Clinical Resources: Administering Vaccines main page
- Immunize.org: Clinical Resources A–Z main page, where you can filter by topic, vaccine, language, or other criteria
Influenza activity declining, RSV persists in the North, and COVID-19 declining nationally; vaccination still offers protection
- Influenza (data through March 14):
- Seasonal influenza activity trending downward across the country, with high or very high levels of influenza-like illness (ILI) reported in 10 jurisdictions
- There have been at least 28 million illnesses, 360,000 hospitalizations, and 22,000 deaths from flu so far this season according to CDC estimates
- Deaths of 14 more children were reported during week 10, for a total of 115 child deaths with influenza reported so far this season
- RSV:
- The Epidemic Trends map shows that RSV activity is growing or likely growing in four northern states
- Respiratory Illnesses Data Channel states that RSV activity started later than expected in most regions, and higher levels of RSV activity may continue into April
- Consult state public health authorities for guidance on how long to continue administering RSV preventive antibody products to infants as the RSV season persists
- COVID-19: Activity is decreasing nationally
Level of Respiratory Illness Activity
The ILI map is shown below.

RSV epidemic trends are shown below:

Vaccination against COVID-19, influenza, and RSV reduces the risk of severe illness and should continue. Immunization of eligible infants against RSV is crucial through March. Follow guidance of public health officials for RSV immunization recommendations beyond March.
On March 13, FDA expanded the indicated age range for Arexvy (RSV vaccine, GSK). This approval expands the indication to include adults age 18 through 49 years who are at increased risk for lower respiratory tract disease (LRTD) due to RSV. Arexvy should not be used during pregnancy. Arexvy’s license continues to include adults age 60 years or older and adults age 50 through 59 years with high-risk conditions for severe RSV disease.
Due to the stay of ACIP activities, it is not known when CDC recommendations for use of this product will be considered.
Three RSV vaccines are now licensed for all adults age 60 years or older AND adults age 18 through 59 years with high-risk conditions for severe RSV disease:
Related Links
- FDA: Arexvy web page
- FDA: Arexvy package insert (PDF)
- FDA: Novel Drug Approvals for 2026 web page
- Immunize.org: Package Inserts and FDA Product Approvals main page
These recent articles convey the potential risks of vaccine-preventable diseases and the importance of vaccination.
- Reuters: Child Vaccination Rate Drops Sharply in Michigan Under RFK Jr’s Influence (3/19/26)
- The Hill: Fewer Americans Trust Government’s Childhood Vaccine Recommendations: Survey (3/17/26)
- New York Times: Health Groups Hailed a Vaccine Ruling, but Their Relief May Be Short-Lived (3/17/26)
- The Guardian: Officials ‘Missed 99% of Data’ Before Ending COVID Vaccine Recommendation, Memos Reveal (3/16/26)
- NPR: In South Carolina, Measles Shows How Far Apart Neighbors Can Be on Vaccines (3/14/26)
- NYC Health: NYC Health Department Launches $1 Million Media Campaign, “Ask Questions, Get Answers, Vaccinate” (3/9/26)
Immunize.org Website and Clinical Resources
![]()
This week’s Spotlight focuses on the footer content found at the bottom of each web page of Immunize.org.
The first section links to our six affiliated websites. Each website supports various aspects of our mission.
- VaccineInformation.org: providing resources to the public about vaccines and vaccine-preventable diseases
- ImmunizationCoalitions.org: providing information to coalitions about and for the National Network of Immunization Coalitions
- LetsGetRealAboutVaccines.org: answering parents’ and providers’ questions about pediatric vaccines and diseases
- Influenza-defense.org: the 65+FluDefense site sharing the essentials of protecting older adults from influenza each year
- Give2MenAcwy.org: sharing resources to support vaccination with two doses of MenACWY vaccine to fully protect adolescent patients
- Izsummitpartners.org: the National Adult and Influenza Immunization Summit (NAIIS) site providing information and resources for the many organizations that address influenza and adult vaccination issues
The dark-blue section below the affiliated sites links to:
- Our social media pages
- Information about Immunize.org, including "Our Mission" and "Our People"
- Ways to support our work: “Shop” and “Donate”
- How to contact us, including an online form
- Subscription information for IZ Express
To learn more, you can watch this related video: Introducing Immunize.org (3 minutes)
The Child Neurology Society released a video, Neurologic Complications of Measles Virus in Children, featuring Celia Greenlaw, MD, neurology fellow, Boston Children's Hospital, and Aaron Nelson, MD, professor of neurology and pediatric neurologist. These neurologists discussed the potential neurologic complications of measles infection.
Complications include acute measles encephalitis and subacute sclerosis panencephalitis (SSPE).
Although rare, SSPE is a devastating, fatal disease that occurs years after measles infection and typically impacts children infected with measles at a young age. Their tips include prevention of acute and late neurologic complications of measles via vaccination and high levels of herd immunity.

View the video.
Observed April 6–10 this year, Adolescent Immunization Action Week (#AIAW26) urges parents, healthcare providers, and adolescents to start the conversation about the vaccines adolescents need to keep their health on track.

Unity’s Partner Toolkit includes ready-to-use graphics, social media templates, sample newsletters, posters, and flyers to support this goal. Resources can be customized and co-branded to meet your needs.
Among these resources is a video public service announcement (PSA) conveying that, while parenting teens can be complicated, supporting their health need not be. You can watch, download, and share the PSA video via the linked graphic below.

Visit Unity’s AIAW campaign page for social media-ready materials to draw attention to improving coverage. Use the hashtag #AIAW26 to spread the word.
Laminated VIS QR code tables deliver CDC VISs directly to your patients’ smartphone (Spanish translation version also available). Now shipping!
The Immunize.org team now offers durable, laminated tables of QR codes linking to VISs for vaccines given to children and adults. VISs explain both risks and benefits of vaccination. Federal law requires you to document provision of CDC’s current VIS before administering any vaccine covered by the Vaccine Injury Compensation Program. CDC recommends VISs accompany other vaccines, too. An easy, paperless way to comply with the law is for patients to scan a QR code and access the VIS from a smartphone or tablet.
CDC produces official VISs only in English. CDC does not produce or certify available translations, so the official CDC VIS should accompany any translation.
These new tables belong in any room where vaccinations are given. Key features include:
- Use as a booklet or poster: The laminated table arrives folded like a newspaper. It is suitable for desk use as an 8.5" x 11" booklet or wall mounted as an 11" x 17" poster.
- Durable quality: The tough laminate coating can be wiped down.
- Never out-of-date: Any time a VIS or translation is updated, the QR code will direct to the new VIS.
- One version for official CDC VISs and one for Spanish translations: The table of official CDC VISs in English is sold individually. The table of Spanish translations is sold as a bundle with the table of official VISs, so it is easy to make both available.
- Spanish version usable by non-Spanish speakers: The Spanish QR code table has side-by-side text in English to support its use by non-Spanish speakers.
- Easy access to all available translations: Both versions include a QR code link to the Immunize.org index of all VIS translations available in dozens of languages.
- Bonus content: The reverse side of the QR code poster includes links to Immunize.org's “Addressing Vaccination Anxiety” resources and additional VIS content.
Pricing (includes all shipping and handling costs)
Laminated CDC VIS QR Code Table (English)
1 copy: $14.00
2 copies: $9.00 each
3–4 copies: $6.50 each
5–9 copies: $5.00 each
10–19 copies: $4.00 each
20–59 copies: $3.00 each
60+ copies: $2.50 each
Bundle: Laminated CDC (English) + Spanish Translation VIS QR Code Tables
(each bundle includes 1 CDC VIS table and 1 table of Spanish translations)
1 bundle: $20.00
2 bundles: $16.00 each
3–4 bundles: $12.00 each
5–9 bundles: $8.50 each
10–19 bundles: $7.00 each
20–59 bundles: $6.00 each
60+ bundles: $5.00 each

Visit the Shop Immunize.org: Laminated VIS QR Code Tables web page to view images and order today! For additional information, call 651-647-9009 or email admininfo@immunize.org
Immunize.org is pleased to introduce our newest lapel pin. Our 2025 Vaccination Saves Lives pins are meaningful gifts for people who understand that lives are not saved by vaccines on a shelf, but by the act of vaccination. The pin makes a refined statement in rich blue enamel with gold lettering and edges, measuring 1.65" x 0.75".

Select the design that best suits how you plan to use your pin:
- Double stick-through posts: Two posts slide through fabric and are held securely by either rubber or locking-metal backings. Both types of backing are provided in the package.
- New! Magnetic clasp: Hold the pin firmly in place without piercing clothing.
Be first in your office to wear these elegant new pins on clothing, white coats, backpacks, or tote bags to remind everyone you meet of the value of vaccination.
Click here for Vaccination Saves Lives pin pricing and ordering information.
Confident healthcare provider recommendations for influenza vaccine are powerfully persuasive. As the nation faces a challenging influenza season, Immunize.org, in collaboration with CSL Seqirus, updated the 65+ Flu Defense website to help you maximize patient protection.

This helpful site includes information, tools, and tips for communicating with adults age 65 and older about the burden and severity of influenza. Resources include:
- Influenza in Adults 65+: The Facts
- Influenza Vaccination: Questions Patients Aged 65 and Older Frequently Ask Their HCP
- The Importance of Preventing Influenza and COVID-19
A clinician recommendation is the most important reason why a person will get vaccinated. Check out the updated 65+ Flu Defense website to assist your ongoing efforts in protecting this vulnerable population.
CDC published Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2—Worldwide, November 2024–February 2026 on March 19 in MMWR. A portion of the summary appears below.
CDC tracks SARS-CoV-2 variants internationally using digital public health surveillance and in the United States using genomic surveillance, including wastewater and traveler-based surveillance. The highly divergent SARS-CoV-2 variant BA.3.2 was first detected in a respiratory sample collected on November 22, 2024, in South Africa. . . .
As of February 11, 2026, BA.3.2 had been reported in 23 countries. Detections began increasing in September 2025. In the United States, BA.3.2 was detected in nasal swabs from four travelers, three airplane wastewater samples, clinical samples from five patients, and 132 wastewater samples from 25 U.S. states. . . .
Monitoring the spread of BA.3.2 provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from a previous infection or vaccination.

Access the MMWR article in HTML or PDF.
Related Link
- CDC: MMWR main page providing access to the MMWR family of publications
Pan American Health Organization issues alert regarding sustained yellow fever transmission in parts of South America
On March 13, the Pan American Health Organization (PAHO) issued a health alert warning of sustained yellow fever transmission in parts of South America, including areas beyond the traditional hotspots of the Amazon basin.
Since September 2024, yellow fever cases were reported in areas beyond the usual patterns. In 2025, 346 confirmed cases and 143 deaths were reported across seven countries: Bolivia, Brazil, Colombia, Ecuador, Guyana, Peru, and Venezuela. During the first seven weeks of 2026, 34 human cases and 15 deaths were confirmed in Bolivia, Colombia, Peru, and Venezuela.
Yellow fever is a mosquito-borne viral disease that can cause severe illness with a high fatality rate. There is no specific treatment. Vaccination is the most effective way to prevent the disease. A single dose provides lifelong protection for most recipients. Most confirmed cases in 2025 and 2026 were reported in people who were not vaccinated. Travelers should get vaccinated at least 10 days before visiting areas where the disease circulates regularly, following international health recommendations.

Related Links
- PAHO: PAHO Reports Sustained Yellow Fever Transmission in Parts of South America (3/13/26)
- Immunize.org: Vaccines A–Z: Yellow Fever main page
The Unity Consortium will host a webinar titled Who Influences Young People’s Health Choices? The New Conversation About Vaccines at 12:00 p.m. (ET) on April 8. During Adolescent Immunization Action Week (April 6–10), Unity and the Clinton Foundation are collaborating to improve adolescent health and vaccination. Parents of adolescents and young adults, vaccinators, educators, and advocates are invited to a 1-hour live webinar to help foster an environment where vaccination is a positive choice for the health of young people.

The webinar will be moderated by Chelsea Clinton, DPhil, MPH, vice chair, Clinton Foundation. Panelists will include Elisabeth Marnik, PhD, The Evidence Collective; Margot Savoy, MD, MPH, American Academy of Family Physicians; and Jessica Steier, DrPH, PMP, Unbiased Science and The Science Literacy Lab.
Register for the webinar.
Virtual: Register for Immunize.org Website Office Hours. Join a 30-minute discussion about our About Us, Publication Archives, and Vaccine Timeline web content on April 8 at 4:00 p.m. (ET) or April 9 at 12:00 p.m. (ET). Recorded sessions archived.
To learn simple tips and tricks for using our websites efficiently, please register for our next set of Website Office Hours on Wednesday, April 8, at 4:00 p.m. (ET) or Thursday, April 9, at 12:00 p.m. (ET). The same content will be covered in both sessions.
We will open each 30-minute session with a short, live demonstration on navigating our About Us, Publication Archives, and Vaccine Timeline website sections. You can submit questions when you register or live on Zoom during the session.

Register today for Immunize.org Website Office Hours (content is the same for both):
The archive of previous Website Office Hours content is posted at Immunize.org’s "Webinars & Videos" page.
Mark your calendar for future Immunize.org Website Office Hours.
For more upcoming events, visit our Calendar of Events.
About IZ Express
IZ Express is supported in part by Grant No. NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of Immunize.org and do not necessarily represent the official views of CDC.
IZ Express Disclaimer
ISSN 2771-8085
Editorial Information
-
Editor-in-ChiefKelly L. Moore, MD, MPH
-
Managing EditorJohn D. Grabenstein, RPh, PhD
-
Associate EditorSharon G. Humiston, MD, MPH
-
Writer/Publication CoordinatorTaryn Chapman, MS
Courtnay Londo, MA -
Style and Copy EditorMarian Deegan, JD
-
Web Edition ManagersArkady Shakhnovich
Jermaine Royes -
Technical ReviewerKayla Ohlde

